- $41.80m
- $46.10m
- $13.07m
Annual income statement for RADNOSTIX,., fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.66 | 11.2 | 12.3 | 13.9 | 13.1 |
| Cost of Revenue | |||||
| Gross Profit | 5.74 | 6.29 | 7.38 | 8.65 | 7.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 10.3 | 12.4 | 13 | 13.9 | 14 |
| Operating Profit | -0.681 | -1.2 | -0.776 | 0.007 | -0.956 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.789 | 0.303 | -0.869 | 0.009 | -0.908 |
| Net Income After Taxes | -0.789 | 0.303 | -0.869 | 0.009 | -0.908 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.902 | 0.303 | -0.869 | 0.009 | -0.908 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.902 | 0.303 | -0.869 | 0.009 | -0.908 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.002 | 0.001 | -0.002 | 0.001 | -0.001 |